Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The study concludes that when there is predisposition of OCPs and upregulation of CYP1A1 gene, then the result will be an increment in hematuria episodes which indicates that gene-environment interaction plays a significant role in the causation of UBC among North Indian population.
|
29027484 |
2018 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis showed that there was no significant association between the two common mutations of CYP1A1 and BC risk.
|
24935599 |
2014 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results revealed positive significant correlations between CYP1A1 genetic polymorphisms and an increased risk of bladder cancer among Asians (allele model: OR=1.33, 95%CI=1.08-1.65, p=0.009; dominant model: OR=1.37, 95%CI=1.02-1.85, p=0.034; respectively), but not among Caucasians (all p<0.05).
|
24552248 |
2014 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated CYP1A1 expression was shown in human bladder cancer relative to normal human tissues.
|
23033491 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that inherited absence of GSTT1 gene may be associated with bladder cancer susceptibility, and specific combinations of GSTM1, GSTT1 and CYP1B1 gene polymorphisms may modify bladder cancer risk in the Turkish population, without any association being observed for CYP1A1 gene polymorphism and bladder cancer risk.
|
23886208 |
2013 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We suggest that the CYP1A1 Ile/Ile genotype with GSTM1 null genotype combination may contribute to the development of bladder cancer in this Turkish population.
|
21709011 |
2011 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we showed that expression of CYP1A1 and CYP1B1 was reduced significantly in an independent cohort of bladder cancer specimens compared with matched benign adjacent tissues.
|
21990318 |
2011 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No statistically significant effects on BC risk with CYP1A1, CYP11B1 and COMT genotypes were observed.
|
19443378 |
2009 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No differences for GSTM1 and GSTP1 genotype prevalence between the bladder cancer cases and the controls were observed, however, the null genotype for the GSTT1 gene and the A/G and G/G variants of the CYP1A1 gene may contribute to the development of bladder cancer.
|
18979064 |
2009 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We observed non-significant association in T/C polymorphism of the CYP1A1 gene (CYP1A1*2A); however, the exon 3 His genotype of the mEH gene polymorphism alone (odds ratio = 2.67, P = 0.001) or in combination with tobacco-users were significantly associated with the risk of bladder cancer.
|
18200441 |
2008 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on a test for trend, we observed 10 non-redundant single-nucleotide polymorphisms (SNPs) in five genes (AKR1C3, ARNT, CYP1A1, CYP1B1 and SULT1A2) significantly associated with bladder cancer risk.
|
18632753 |
2008 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most notable findings are: GSTM1 deletion and bladder cancer risk [odds ratio (OR) = 1.60; 95% confidence interval 1.00-2.56]; CYP1A1 and leukemia (2.22, 1.33-3.70; heterozygotes); CYP1B1 and leukemia (0.47, 0.27-0.84; homozygotes); MnSOD and leukemia (1.91, 1.08-3.38; homozygotes) and NQO1 and lung cancer (8.03, 1.73-37.3; homozygotes).
|
17496311 |
2007 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 may have a role in bladder cancer risk, but polymorphisms in CYP1A1 and 2E1 had no statistically significant impact.
|
8752158 |
1996 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, AHH acitivity or inducibility does not appear to be a major determinant of bladder cancer risk in humans.
|
437914 |
1979 |